LitAlert ~~ GeneLit.com

    • PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
    • Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G.
    • Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.
    • Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2020 Aug 24. doi: 10.1007/s00404-020-05677-1. Epub ahead of print.
    • Breast cancer (BRCA) gene testing in ovarian cancer.
    • Chelariu-Raicu A, Coleman RL.
    • Chin Clin Oncol. 2020 Aug 19:cco-20-4. doi: 10.21037/cco-20-4. Epub ahead of print.
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
    • de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT.
    • NPJ Breast Cancer. 2020 Aug 7;6:33. doi: 10.1038/s41523-020-0172-0.
    • Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig? [Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?].
    • Schmidt M.
    • J Gynakol Endokrinol. 2020 Jun 2:1-3. German. doi: 10.1007/s41974-020-00141-z. Epub ahead of print.